Summit and Akeso's ivonescimab attracted headlines earlier this year when it was shown to be more effective than anti-PD-1 ...

"Slingshot represents an opportunity to bridge the gap between academic innovation and clinical development of a novel ...

GSK's drive to resurrect its multiple myeloma therapy Blenrep has continued with new data from the DREAMM-7 trial showing an ...

The sizeable new round follows the announcement of phase 1 data for its lead asset MET-097i in September and, according to ...

Kebilidi is the first gene therapy approved by the FDA for administration directly into the brain, given via a cannula during ...

The 21st century pharmaceutical and biotech sector has come a long way from its roots in 19th century pharmacy. pharmaphorum looks at its evolution over the centuries. The roots of the ...

MSD and Moderna have kicked off another phase 3 trial of their personalised cancer vaccine V940 used alongside MSD's PD-1 inhibitor Keytruda, this time focusing on patients with earlier-stage non ...

AstraZeneca has agreed a deal worth up to $247 million with US generative artificial intelligence (GenAI) company Absci that will focus on the discovery of a new antibody-based drug for cancer.

Celadon Pharmaceuticals has secured the final approval needed to start a large-scale trial of its cannabinoid therapy for chronic pain in the UK. The AIM-listed company said this morning that the ...

The FDA's Prescription Drug Use-Related Software (PDURS) framework marks a significant milestone for healthcare in the US. Introduced to facilitate the integration of software with prescription ...

The team that brought you Karuna – recently sold to Bristol-Myers Squibb for $14 billion – has set up a neuropsychiatry-focused biotech called Seaport Therapeutics. Karuna co-founder Daphne ...

Cassava is advancing simufilam through a pivotal phase 3 trial, despite lingering controversy from a SEC investigation. As the company prepares to release trial results, Ben Hargreaves finds that ...